57results about How to "Increase route of administration" patented technology

The invention relates to daidzein micelles and a preparation method thereof. The daidzein micelles contain 1 part of daidzein, 12 to 30 parts of phospholipid and 1 to 25 parts of additive. The preparation method comprises: preparing a daidzein and phospholipid composite, namely, adding daidzein and 50 to 95 percent of phospholipid into an organic solvent, heating the solution to 40 to 60 DEG C, refluxing under reduced pressure, keeping temperature and stirring for 2 to 10 hours, recovering the organic solvent, drying and crushing to obtain the daidzein and phospholipid composite; and preparing daidzein micelles from the phospholipid composite, namely, dissolving the daidzein and phospholipid composite, the rest phospholipid and the additive in an organic solvent, subjecting the solution to rotary evaporation to form a film, and hydrating at 40 to 60 DEG C to obtain daidzein micelle suspension with opalescence. The average particle size of the daidzein micelles is less than 50 nanometers. The daidzein micelles can be further prepared into oral or injection preparations including capsules, oral mixed suspension, oral liquid, injection, injection freeze-dried powder injection.

This invention discloses a method for preparing fibrauretine derivative with antibacterial, anti-inflammatory, cardiomyocyte protective and anti-arrhythmia functions. The method comprises: dissolving fibrauretine in 0-100 deg.C water, adding the same mol amount of alkali or salt containing Na+ or K+, reacting under stirring and normal pressure to obtain transparent liquid with the color from orange to bordeaux and a pH value of 7.0-12.5, sterilizing, filtering, and heating or vacuum-drying at low temperatures to obtain solid fibrauretine derivative with the color from light yellow to dark brown. The fibrauretine derivative has improved water solubility, absorbency, bioavailability and therapeutic effects, newly developed administration method and dosage form, and widened clinical applications.

The invention belongs to the technical field of traditional Chinese medicine preparations for beasts, and particularly relates to a traditional Chinese medicine preparation for preventing weaned piglets from suffering diarrhea, and a preparation method of the traditional Chinese medicine preparation. The traditional Chinese medicine preparation is mainly prepared from the following raw materials in parts by weight: plant extracts and glucose, wherein the plant extracts comprise dandelion extracts, astragalus membranaceus extracts, herba andrographitis extracts, and cordate houttuynia extracts. The preparation method of the medicine preparation comprises the following steps: sieving the plant extracts with a sieve of 50-70 meshes, uniformly mixing the sieved plant extracts, adding the glucose sieved by a sieve of 70-100 meshes in the mixed plant extracts, and uniformly mixing the sieved glucose with the mixed plant extracts so as to obtain the traditional Chinese medicine preparation. The traditional Chinese medicine preparation for preventing weaned piglets from suffering, disclosed by the invention, has significant effects of resisting bacteria and resisting viruses, and can significantly reinforce the immunity of weaned piglets; the traditional Chinese medicine preparation is rich in nutritional substances, so that the nutritional needs of weaned piglets can be met; the traditional Chinese medicine preparation has the advantages that the gastroenteric functions of weaned piglets can be regulated, the absorption of nutritional substances can be promoted, the daily gain of weaned piglets can be increased, and the feed converting rate can be increased, so that the phenomenon that the weaned piglets are liable to get diarrhea is effectively avoided.

This invention supplies a method for preparing nanorealgar colloid and nanorealgar through modulating their appearance and particle size with biology macromolecular mold. Its characteristic is: chemically remove arsenic and impurity elements from natural realgar mine, make nanorealgar colloid and nanorealgar by taking biology macromolecular as mold to modulate the appearance and particle size, so nanorealgars of various appearance and particle size can be prepared by changing mold varieties and ageing conditions. This invention has broad processing raw materials, and the yielded nanorealgar has high purity, uniform particle size, good water-solubility, it is uneasy to oxidation or reunion and has obverse synergism effect with mold molecule. It can markedly strengthen the effect of realgar antibiosis and anti-tumour, improve realgar biology availability, depress realgar toxic side effect and expand realgar route of administration.

The invention relates to a traditional Chinese medicine composition, in particular to a traditional Chinese medicine composition for reducing lipid, discharging turbidity and clearing intestines, application thereof and a preparation method therefor, and overcomes the problem that such existing drugs have large toxic and side effects and a poor curative effect. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials in parts by weight: 8-10 parts of radix bupleuri, 8-12 parts of radix scutellariae, 10-20 parts of semen cassiae, 10-15 parts of fructus crataegi, 10-20 parts of semen cannabis and 10-20 parts of semen pruni. The traditional Chinese medicine composition has the effects of clearing liver and removing blood stasis, removing dampness and purging turbidity, and can be deeply retained locally by whole colon irrigation, and accordingly, the purposes of regulating intestinal floras, reducing lipid and losing weight, reducing inflammations and discharging turbidity are achieved; and the traditional Chinese medicine composition is mainly used for patients with fatty liver and patients with hyperlipemia and metabolicsyndromes, and stagnated heat in liver meridian by TCM syndrome differentiation, has a significant curative effect, and is safe and non-toxic.

The invention relates to solid lipid nanoparticles of daidzein which is a hydrophobic medicine and a preparation method thereof. The average particle size of the solid lipid nanoparticles of daidzein is less than 100 nanometers; and based on weight part, the solid lipid nanoparticles comprise 1 part of daidzein, 5 to 30 parts of phospholipid, 1 to 50 parts of surfactant and 1 to 40 parts of solidlipid material, wherein the daidzein and phospholipid form a composite which is covered by solid lipid or the solid lipid and phospholipid. The daidzein solid lipid nanoparticles are prepared by a thin-film dispersion method or hot-melt dispersion method. The preparation method comprises: forming a composite of the daidzein and phospholipid; and covering the composite with the solid lipid nanoparticles for solving the problems of low solubility, low stability and preparation difficulty in preparation process of the daidzein. The average particle size of the solid lipid nanoparticles is less than 100 nanometers, and the rate of in-vitro release in 8 hours reaches 58.4 percent, and the oral bioavailability is high; and the solid lipid nanoparticles can be further prepared into capsules, oral suspension, oral liquid and other oral preparation, and can make the medicine taken by the patient easily.

The invention discloses a preparation method of a water-soluble acanthopanax powder capsule, and belongs to the technical field of extraction and processing of plant rhizomes. According to the preparation method, the acanthopanax is taken as a raw material, saponin is dissolved out by adopting ethanol reflux extraction, and the water-soluble acanthopanax powder capsule is obtained through spray drying after being wrapped by chitosan oligosaccharide, so that the technological process is green, environment-friendly, simple and convenient to operate and good in dissolution property, and can be easily amplified to industrial production; a new thought is provided for development and utilization of water-soluble preparation of other Chinese herbal medicines insoluble in water, and the administration route and the use object are further widened; and in addition, the clathrate compound prepared by the invention is high in bioavailability, so that the curative effect of the clathrate compound is greatly improved, and the treatment cost is greatly reduced. Therefore, the technical scheme disclosed by the invention has great market application and popularization values.

The invention belongs to the field of bio-medicines, and particularly relates to an application of a hemopoietin sourced peptide in preparation of a medicine for treating the metabolic syndrome. The application includes an application of preparation of medicines for treating obesity, diabetes mellitus and hyperlipemia, The hemopoietin sourced peptide can be prepared into lipidosome, and the metabolic syndrome can be treated by the hemopoietin sourced peptide and the hemopoietin sourced peptide lipidosome, the syndromes of the hemopoietin sourced peptide are remarkably relieved after treatment, and the effect of the hemopoietin sourced peptide lipidosome is superior to that of the hemopoietin sourced peptide, and the administration frequency can be reduced. The application of the hemopoietin sourced peptide lipidosome to medicines can be used for prolonging the medicine acting period, increasing the lipid solubility and stability of the medicines and reducing toxic and side effects. Therefore, compared with an independent application of micro-molecule polypeptide, lipidosome coated micro-molecule polypeptide has the advantages of prolonging half-life period, improving stability and lipid solubility and increasing administration routes. The hemopoietin sourced peptide has an important clinical application value.

The invention discloses a compound shown in a formula (I) (described in the specification), wherein R is selected from two groups (described in the specification). The compound shown in the formula (I) can inhibit production of IL-12 in vitro and shows excellent activity in an SD rat collagen-induced rheumatoid arthritis model. Therefore, the compound shown in the formula (I) can be researched anddeveloped more deeply as a candidate drug for preparation of medicines used for preventing and / or treating rheumatoid arthritis.

The invention relates to a cinnamomum longepaniculatum leaf volatile oil beta-cyclodextrin clathrate compound serving as a functional biological feed additive and a preparation method thereof. The preparation method comprises the following steps of: adding cinnamomum longepaniculatum leaf volatile oil dissolved in an organic solvent into aqueous solution containing beta-cyclodextrin, and stirring. The cinnamomum longepaniculatum leaf volatile oil beta-cyclodextrin clathrate compound has the characteristics of mild clathrate condition, simplicity of operation, easy control and high clathrate yield. The prepared clathrate compound makes the cinnamomum longepaniculatum leaf volatile oil in the solid state and convenient to mix for livestock and poultry, the medicinal effect of the volatile oil can be protected, and the palatability is improved, so the defects of irritation, volatility and the like due to the direct adoption of the volatile oil are overcome. The clathrate compound has theeffects of resisting bacteria (escherichia coli, salmonella and staphylococcus aureus), resisting fungi (trichophyton mentagrophytes, microsporum canis and microsporum gypseum), killing insect pests,easing pain and resisting inflammation, and is a good biological feed additive which is used for resisting diseases and promoting growth and avoids residue.

The invention relates to the technical field of medicine and particularly relates to a preparation of topiroxostat liposome and a preparation method thereof. The preparation of topiroxostat liposome comprises, by weight, 1 to 3 parts of topiroxostat, 30 to 90 parts of phospholipid and 10 to 50 parts of cholesterol. The preparation of topiroxostat liposome can be processed into a freeze-dried powder injection. The freeze-dried powder injection comprises, by weight, 1 to 3 parts of topiroxostat, 30 to 90 parts of phospholipid, 10 to 50 parts of cholesterol, 5 to 20 parts of a lyoprotectant and 0 to 10 parts of a redissolution aid. The preparation of topiroxostat liposome has high encapsulation efficiency, uniform particle sizes and stable quality. The preparation method has simple processes, increases the administration path of topiroxostat and improves patient compliance. The topiroxostat liposome prolongs the action time of topiroxostat and produces unexpected technical effects.